Data quality in rare cancers registration: the report of the RARECARE data quality study
|Published in||Tumori. 2017, vol. 103, no. 1, p. 22-32|
|Abstract||Rare cancers represent 22% of all tumors in Europe; however, the quality of the data of rare cancers may not be as good as the quality of data for common cancer. The project surveillance of rare cancers in Europe (RARECARE) had, among others, the objective of assessing rare cancer data quality in population-based cancer registries (CRs). Eight rare cancers were considered: mesothelioma, liver angiosarcoma, sarcomas, tumors of oral cavity, CNS tumors, germ cell tumors, leukemia, and malignant digestive endocrine tumors.|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research group||Groupe Bouchardy Magnin Christine (Registre genevois des tumeurs) (532)|
|TRAMA, Annalisa et al. Data quality in rare cancers registration: the report of the RARECARE data quality study. In: Tumori, 2017, vol. 103, n° 1, p. 22-32. doi: 10.5301/tj.5000559 https://archive-ouverte.unige.ch/unige:89125|